[{"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-001", "question": "A 6-year-old boy with a history of Diamond-Blackfan anemia (DBA) treated with chronic corticosteroids and transfusions presents with progressive dyspnea and fatigue. Echocardiography reveals a restrictive cardiomyopathy with severe biventricular diastolic dysfunction and moderate pulmonary hypertension. Genetic testing confirms a pathogenic variant in RPS19. Which of the following is the most appropriate next step in management?", "options": ["Initiation of high-dose beta-blockers and ACE inhibitors", "Referral for combined heart-lung transplantation evaluation", "Immediate discontinuation of corticosteroids and transition to defibrotide", "Addition of L-leucine supplementation to current regimen", "Cardiac MRI with T1 mapping and extracellular volume quantification"], "answer": "D", "answer_index": 3, "explanation": "Diamond-Blackfan anemia is associated with ribosomal protein mutations, and L-leucine has been shown to improve ribosomal function and hematopoiesis in DBA. In patients with DBA-associated cardiomyopathy, addressing the underlying ribosomal dysfunction with leucine supplementation may improve cardiac function, whereas conventional heart failure therapies are less effective for this specific pathophysiology. Beta-blockers/ACE inhibitors would be insufficient, transplantation is premature without addressing the underlying metabolic defect, defibrotide is for hepatic veno-occlusive disease, and advanced imaging would not change management.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "```json\n{\n    \"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - unique best answer exists but keyed answer D is not it. Key stem clues: DBA with restrictive cardiomyopathy, severe diastolic dysfunction, pulmonary hypertension, on chronic steroids/transfusions. Main logical issue: Key D (L-leucine) is experimental/unproven for DBA cardiomyopathy, while option B (transplant evaluation) is standard of care for end-stage restrictive cardiomyopathy with severe dysfunction and pulmonary hypertension. Main medical accuracy issue: Recommending experimental leucine over established transplant evaluation for severe symptomatic disease contradicts standard cardiology practice. Minimal fix: Change key to B and adjust rationale to reflect that severe symptomatic restrictive cardiomyopathy with pulmonary hypertension warrants transplant evaluation regardless of underlying DBA.\",\n    \"medical_accuracy_score\": 2,\n    \"logical_validity\": false,\n    \"logical_false_reason\": \"K\"\n}\n```", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - unique best answer exists but keyed answer D is not it. Key stem clues: DBA with restrictive cardiomyopathy, severe diastolic dysfunction, pulmonary hypertension, on chronic steroids/transfusions. Main logical issue: Key D (L-leucine) is experimental/unproven for DBA cardiomyopathy, while option B (transplant evaluation) is standard of care for end-stage restrictive cardiomyopathy with severe dysfunction and pulmonary hypertension. Main medical accuracy issue: Recommending experimental leucine over established transplant evaluation for severe symptomatic disease contradicts standard cardiology practice. Minimal fix: Change key to B and adjust rationale to reflect that severe symptomatic restrictive cardiomyopathy with pulmonary hypertension warrants transplant evaluation regardless of underlying DBA.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-002", "question": "A 34-year-old pregnant woman at 32 weeks gestation presents with acute-onset severe hypertension (200/120 mmHg), headache, and visual disturbances. Laboratory studies show thrombocytopenia (platelets 85,000/μL), elevated liver enzymes (AST 250 U/L, ALT 280 U/L), and creatinine 1.8 mg/dL. Magnesium sulfate is initiated. Despite aggressive antihypertensive therapy with labetalol and hydralazine, her blood pressure remains persistently elevated. Which of the following is the most appropriate next pharmacologic intervention?", "options": ["Immediate initiation of nitroprusside infusion", "Addition of oral nifedipine XL 30 mg daily", "Intravenous fenoldopam infusion titrated to effect", "Sublingual captopril 12.5 mg repeated every 30 minutes", "Intravenous esmolol bolus followed by continuous infusion"], "answer": "C", "answer_index": 2, "explanation": "Fenoldopam is a dopamine-1 receptor agonist that causes vasodilation without compromising uteroplacental blood flow and is safe in pregnancy for refractory hypertension. Nitroprusside is contraindicated due to risk of cyanide toxicity to the fetus. Nifedipine XL has slow onset and is inadequate for acute control. ACE inhibitors like captopril are contraindicated in pregnancy due to fetal renal toxicity. Esmolol may cause fetal bradycardia and is less ideal than fenoldopam for pregnancy-associated hypertensive emergencies.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "```json\n{\n    \"analysis\": \"Validity label: K (Miskeyed). Verdict on keyed answer: Miskeyed. Key stem clues: 32-week pregnant patient with severe preeclampsia/HELLP syndrome, refractory hypertension despite labetalol and hydralazine. Main logical issue: Fenoldopam (keyed answer C) is not the standard next-line agent for refractory hypertension in preeclampsia. Main medical accuracy issue: Current ACOG/SMFM guidelines recommend intravenous labetalol, hydralazine, or oral nifedipine as first-line agents; for refractory cases, nicardipine or clevidipine are preferred over fenoldopam. Fenoldopam is rarely used and not guideline-recommended as first alternative. Minimal fix: Change key to B (oral nifedipine) and update rationale to reflect that oral nifedipine is guideline-supported for acute severe hypertension in pregnancy when IV access is limited or as adjunct therapy.\",\n    \"medical_accuracy_score\": 3,\n    \"logical_validity\": false,\n    \"logical_false_reason\": \"K\"\n}\n```", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict on keyed answer: Miskeyed. Key stem clues: 32-week pregnant patient with severe preeclampsia/HELLP syndrome, refractory hypertension despite labetalol and hydralazine. Main logical issue: Fenoldopam (keyed answer C) is not the standard next-line agent for refractory hypertension in preeclampsia. Main medical accuracy issue: Current ACOG/SMFM guidelines recommend intravenous labetalol, hydralazine, or oral nifedipine as first-line agents; for refractory cases, nicardipine or clevidipine are preferred over fenoldopam. Fenoldopam is rarely used and not guideline-recommended as first alternative. Minimal fix: Change key to B (oral nifedipine) and update rationale to reflect that oral nifedipine is guideline-supported for acute severe hypertension in pregnancy when IV access is limited or as adjunct therapy.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-003", "question": "A 58-year-old man with metastatic renal cell carcinoma on nivolumab and ipilimumab combination therapy presents with acute respiratory failure requiring mechanical ventilation. Bronchoalveolar lavage shows lymphocytic predominance without infectious organisms. High-dose methylprednisolone (2 mg/kg/day) was initiated 72 hours ago without improvement. Which of the following is the most appropriate next step in management?", "options": ["Add infliximab 5 mg/kg single dose", "Initiate cyclophosphamide 1 g/m² IV", "Switch to dexamethasone 40 mg daily", "Begin plasma exchange therapy", "Add tocilizumab 8 mg/kg IV"], "answer": "A", "answer_index": 0, "explanation": "For steroid-refractory immune checkpoint inhibitor-related pneumonitis, TNF-alpha inhibition with infliximab is the recommended next-line therapy based on retrospective evidence showing improved outcomes. Cyclophosphamide is used for other immune-related adverse events like myocarditis but not first-line for pneumonitis. Switching corticosteroids is unlikely to help if already on high-dose methylprednisolone. Plasma exchange is not established for this condition. Tocilizumab (IL-6 inhibitor) is used for cytokine release syndrome but not specifically for checkpoint inhibitor pneumonitis.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "```json\n{\n    \"analysis\": \"Validity label: V. Verdict: Correct best answer. Key stem clues: metastatic RCC on nivolumab+ipilimumab, acute respiratory failure requiring ventilation, BAL showing lymphocytic predominance without infection, steroid-refractory pneumonitis (no improvement after 72h high-dose methylprednisolone). The clinical scenario clearly describes severe, steroid-refractory immune checkpoint inhibitor pneumonitis. The item correctly identifies infliximab as the next step for steroid-refractory immune checkpoint inhibitor pneumonitis per current guidelines. No logical issues: the vignette provides sufficient detail, options are distinct, and the key matches the single best answer. Medical accuracy is sound: infliximab is indeed the recommended next-line therapy for steroid-refractory immune checkpoint inhibitor pneumonitis. Minimal fix: None needed; item is already unambiguous and accurate.\",\n    \"medical_accuracy_score\": 5,\n    \"logical_validity\": true,\n    \"logical_false_reason\": \"T\"\n}\n```", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. Key stem clues: metastatic RCC on nivolumab+ipilimumab, acute respiratory failure requiring ventilation, BAL showing lymphocytic predominance without infection, steroid-refractory pneumonitis (no improvement after 72h high-dose methylprednisolone). The clinical scenario clearly describes severe, steroid-refractory immune checkpoint inhibitor pneumonitis. The item correctly identifies infliximab as the next step for steroid-refractory immune checkpoint inhibitor pneumonitis per current guidelines. No logical issues: the vignette provides sufficient detail, options are distinct, and the key matches the single best answer. Medical accuracy is sound: infliximab is indeed the recommended next-line therapy for steroid-refractory immune checkpoint inhibitor pneumonitis. Minimal fix: None needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-004", "question": "A 3-day-old term neonate presents with poor feeding, lethargy, and hypoglycemia (glucose 25 mg/dL). Physical exam reveals macroglossia, umbilical hernia, and mild hepatomegaly. Newborn screening shows elevated galactose and galactitol. Which of the following additional findings would be most specific for confirming the diagnosis?", "options": ["Elevated serum ammonia level", "Absent reducing substances in urine after lactose challenge", "Normal glycogen content on liver biopsy", "Deficient activity of galactose-1-phosphate uridyltransferase in erythrocytes", "Presence of cataract on ophthalmologic examination"], "answer": "C", "answer_index": 2, "explanation": "The presentation suggests galactosemia, but the key distinguishing feature is that in galactose epimerase deficiency (a rare form), liver biopsy shows normal glycogen content, whereas in classic galactosemia (GALT deficiency), glycogen is depleted. Elevated ammonia suggests urea cycle defect. Absent reducing substances would argue against galactosemia. GALT enzyme deficiency confirms classic galactosemia, not the epimerase variant. Cataracts occur in both forms and are not specific.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "```json\n{\n    \"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - a unique best answer exists (D), but the provided key (C) is incorrect. Key stem clues: term neonate with poor feeding, lethargy, hypoglycemia, macroglossia, umbilical hernia, hepatomegaly, and elevated galactose/galactitol on newborn screening point to galactosemia. The question asks for the most specific confirmatory test. Main logical issue: Option D (enzyme assay) is the gold standard confirmatory test for galactosemia and most specific, while option C (normal glycogen content) is not a standard confirmatory finding for any galactosemia variant. Main medical accuracy issue: The rationale incorrectly states that normal glycogen content distinguishes galactose epimerase deficiency from classic galactosemia; while glycogen may be normal in epimerase deficiency, this is not a specific confirmatory test. Minimal fix: Change the key to D, as enzyme deficiency testing is the definitive diagnostic method for galactosemia.\",\n    \"medical_accuracy_score\": 3,\n    \"logical_validity\": false,\n    \"logical_false_reason\": \"K\"\n}\n```", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - a unique best answer exists (D), but the provided key (C) is incorrect. Key stem clues: term neonate with poor feeding, lethargy, hypoglycemia, macroglossia, umbilical hernia, hepatomegaly, and elevated galactose/galactitol on newborn screening point to galactosemia. The question asks for the most specific confirmatory test. Main logical issue: Option D (enzyme assay) is the gold standard confirmatory test for galactosemia and most specific, while option C (normal glycogen content) is not a standard confirmatory finding for any galactosemia variant. Main medical accuracy issue: The rationale incorrectly states that normal glycogen content distinguishes galactose epimerase deficiency from classic galactosemia; while glycogen may be normal in epimerase deficiency, this is not a specific confirmatory test. Minimal fix: Change the key to D, as enzyme deficiency testing is the definitive diagnostic method for galactosemia.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-005", "question": "A 42-year-old woman with systemic lupus erythematosus and antiphospholipid syndrome on warfarin (INR 2.5-3.5) presents with acute right leg pain and swelling. Doppler ultrasound confirms extensive deep vein thrombosis despite therapeutic anticoagulation. Lupus anticoagulant is positive, and anti-β2-glycoprotein I antibodies are elevated. Which of the following management strategies is most appropriate?", "options": ["Switch to rivaroxaban 20 mg daily", "Increase warfarin target INR to 3.5-4.5", "Add hydroxychloroquine 400 mg daily to current regimen", "Initiate intravenous immunoglobulin 1 g/kg for two days", "Place an inferior vena cava filter"], "answer": "C", "answer_index": 2, "explanation": "In antiphospholipid syndrome with breakthrough thrombosis despite therapeutic warfarin, adding hydroxychloroquine has been shown to reduce thrombotic risk through multiple mechanisms including inhibition of platelet activation and neutralization of antiphospholipid antibodies. Direct oral anticoagulants like rivaroxaban are less effective in triple-positive APS. Higher INR targets increase bleeding risk without proven benefit. IVIG is reserved for catastrophic APS. IVC filters do not address the hypercoagulable state and increase long-term DVT risk.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "```json\n{\n    \"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - a unique best answer exists but keyed answer C is not it. Key stem clues: APS with breakthrough DVT despite therapeutic warfarin (INR 2.5-3.5), triple-positive antibodies. Main logical issue: While hydroxychloroquine has evidence for thromboprophylaxis in APS, the acute management of breakthrough thrombosis requires escalation of anticoagulation intensity. Main medical accuracy issue: Current guidelines (ISTH, ACCP) recommend increasing anticoagulation intensity (INR 3.0-4.0 or LMWH) for breakthrough thrombosis in APS, not adding hydroxychloroquine as acute management. Minimal fix: Change key to B (Increase warfarin target INR to 3.5-4.5) with rationale citing guideline recommendations for intensification.\",\n    \"medical_accuracy_score\": 2,\n    \"logical_validity\": false,\n    \"logical_false_reason\": \"K\"\n}\n```", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - a unique best answer exists but keyed answer C is not it. Key stem clues: APS with breakthrough DVT despite therapeutic warfarin (INR 2.5-3.5), triple-positive antibodies. Main logical issue: While hydroxychloroquine has evidence for thromboprophylaxis in APS, the acute management of breakthrough thrombosis requires escalation of anticoagulation intensity. Main medical accuracy issue: Current guidelines (ISTH, ACCP) recommend increasing anticoagulation intensity (INR 3.0-4.0 or LMWH) for breakthrough thrombosis in APS, not adding hydroxychloroquine as acute management. Minimal fix: Change key to B (Increase warfarin target INR to 3.5-4.5) with rationale citing guideline recommendations for intensification.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-006", "question": "A 67-year-old man with ischemic cardiomyopathy (LVEF 25%) and cardiac resynchronization therapy defibrillator presents with recurrent appropriate shocks for ventricular tachycardia. He is on maximally tolerated doses of carvedilol, lisinopril, and spironolactone. Amiodarone was started but discontinued due to thyroid toxicity. Which of the following is the most appropriate next antiarrhythmic therapy?", "options": ["Mexiletine 200 mg three times daily", "Sotalol 80 mg twice daily", "Dofetilide 500 mcg twice daily with inpatient initiation", "Ranolazine 1000 mg twice daily", "Propafenone 150 mg three times daily"], "answer": "C", "answer_index": 2, "explanation": "Dofetilide is a class III antiarrhythmic that is effective for ventricular tachycardia in structural heart disease and does not have the non-cardiac toxicity profile of amiodarone. It requires inpatient initiation due to risk of torsades de pointes. Mexiletine has limited efficacy as monotherapy. Sotalol is contraindicated in severe systolic dysfunction. Ranolazine has antianginal but limited antiarrhythmic evidence for VT. Propafenone is contraindicated in structural heart disease due to proarrhythmic risk.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "```json\n{\n    \"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - a unique best answer exists but the provided key (C) is not it. Key stem clues: ischemic cardiomyopathy with LVEF 25% (severe systolic dysfunction), recurrent VT despite CRT-D and GDMT, amiodarone discontinued for toxicity. Main logical issue: Dofetilide (C) is contraindicated in severe heart failure (CrCl <60 mL/min in this age group with low EF suggests likely renal impairment). Sotalol (B) is also contraindicated in severe systolic dysfunction. Main medical accuracy issue: The keyed answer (dofetilide) violates standard contraindications for severe structural heart disease. Minimal fix: Change key to D (ranolazine), which has evidence for VT suppression in structural heart disease without negative inotropy, or clarify renal function to justify dofetilide.\",\n    \"medical_accuracy_score\": 2,\n    \"logical_validity\": false,\n    \"logical_false_reason\": \"K\"\n}\n```", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - a unique best answer exists but the provided key (C) is not it. Key stem clues: ischemic cardiomyopathy with LVEF 25% (severe systolic dysfunction), recurrent VT despite CRT-D and GDMT, amiodarone discontinued for toxicity. Main logical issue: Dofetilide (C) is contraindicated in severe heart failure (CrCl <60 mL/min in this age group with low EF suggests likely renal impairment). Sotalol (B) is also contraindicated in severe systolic dysfunction. Main medical accuracy issue: The keyed answer (dofetilide) violates standard contraindications for severe structural heart disease. Minimal fix: Change key to D (ranolazine), which has evidence for VT suppression in structural heart disease without negative inotropy, or clarify renal function to justify dofetilide.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-007", "question": "A 28-year-old primigravida at 36 weeks gestation presents with progressive dyspnea and orthopnea. Echocardiography shows peripartum cardiomyopathy with LVEF 30%. After diuresis with furosemide, she remains symptomatic. Which of the following medications should be avoided until after delivery?", "options": ["Digoxin 0.125 mg daily", "Hydralazine 25 mg three times daily", "Isosorbide dinitrate 20 mg three times daily", "Sacubitril/valsartan 24/26 mg twice daily", "Metoprolol succinate 25 mg daily"], "answer": "D", "answer_index": 3, "explanation": "Sacubitril/valsartan contains an ARB (valsartan) which is contraindicated in pregnancy due to fetal renal toxicity and oligohydramnios risk, particularly in the third trimester. Digoxin, hydralazine, isosorbide dinitrate, and metoprolol are all acceptable in pregnancy for heart failure management. While ACE inhibitors and ARBs are absolutely contraindicated, the other medications listed can be used with appropriate monitoring.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: 36 weeks gestation, peripartum cardiomyopathy with LVEF 30%, symptomatic after diuresis. The question asks for a medication to avoid until after delivery. The unique best answer is the one containing a medication class (ARB/ACEi) with an absolute contraindication in pregnancy. Sacubitril/valsartan (an ARNI containing valsartan) is absolutely contraindicated due to fetal renal toxicity and oligohydramnios. All other options (digoxin, hydralazine, isosorbide dinitrate, metoprolol) are used in pregnancy for heart failure with appropriate monitoring. No logical issues; the stem provides sufficient detail. Medical accuracy is sound, aligning with standard guidelines. Minimal fix: None required for validity; for clarity, the stem could specify 'symptomatic NYHA class III/IV heart failure' to reinforce the need for additional guideline-directed medical therapy beyond diuretics.\",\n  \"medical_accuracy_score\": 4,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: 36 weeks gestation, peripartum cardiomyopathy with LVEF 30%, symptomatic after diuresis. The question asks for a medication to avoid until after delivery. The unique best answer is the one containing a medication class (ARB/ACEi) with an absolute contraindication in pregnancy. Sacubitril/valsartan (an ARNI containing valsartan) is absolutely contraindicated due to fetal renal toxicity and oligohydramnios. All other options (digoxin, hydralazine, isosorbide dinitrate, metoprolol) are used in pregnancy for heart failure with appropriate monitoring. No logical issues; the stem provides sufficient detail. Medical accuracy is sound, aligning with standard guidelines. Minimal fix: None required for validity; for clarity, the stem could specify 'symptomatic NYHA class III/IV heart failure' to reinforce the need for additional guideline-directed medical therapy beyond diuretics.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-008", "question": "A 5-year-old girl with history of recurrent sinopulmonary infections presents with new-onset ataxia and nystagmus. MRI brain shows diffuse cerebellar atrophy. Serum immunoglobulin levels reveal IgG 450 mg/dL, IgA 10 mg/dL, and IgM 15 mg/dL. Flow cytometry shows absent B cells. Which of the following genetic mutations is most likely responsible for this clinical presentation?", "options": ["BTK gene mutation", "CD40 ligand deficiency", "AICDA gene mutation", "RAG1 gene mutation", "ATM gene mutation"], "answer": "E", "answer_index": 4, "explanation": "Ataxia-telangiectasia (ATM gene mutation) presents with combined immunodeficiency (low immunoglobulins, absent B cells), recurrent infections, cerebellar ataxia, and oculomotor apraxia. BTK mutation causes X-linked agammaglobulinemia with absent B cells but no ataxia. CD40 ligand deficiency causes hyper-IgM syndrome with normal or increased IgM. AICDA mutation causes hyper-IgM syndrome type 2. RAG1 mutation causes severe combined immunodeficiency (SCID) but not typically with cerebellar atrophy.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "```json\n{\n    \"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - a unique best answer exists but the provided key (E) is not it. Key stem clues: recurrent sinopulmonary infections, absent B cells, low IgG/IgM/IgA, cerebellar ataxia with atrophy. These point definitively to X-linked agammaglobulinemia (BTK mutation) as the single best answer. Main logical issue: The keyed answer (ATM mutation) contradicts the stem's finding of absent B cells - ataxia-telangiectasia typically has normal or low B cells but not absent. Main medical accuracy issue: ATM mutation would not explain absent B cells. Minimal fix: Change key from E to A (BTK mutation) to match the clinical presentation of agammaglobulinemia with cerebellar involvement (though cerebellar atrophy is atypical for XLA, it's more consistent than ATM given absent B cells).\",\n    \"medical_accuracy_score\": 3,\n    \"logical_validity\": false,\n    \"logical_false_reason\": \"K\"\n}\n```", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - a unique best answer exists but the provided key (E) is not it. Key stem clues: recurrent sinopulmonary infections, absent B cells, low IgG/IgM/IgA, cerebellar ataxia with atrophy. These point definitively to X-linked agammaglobulinemia (BTK mutation) as the single best answer. Main logical issue: The keyed answer (ATM mutation) contradicts the stem's finding of absent B cells - ataxia-telangiectasia typically has normal or low B cells but not absent. Main medical accuracy issue: ATM mutation would not explain absent B cells. Minimal fix: Change key from E to A (BTK mutation) to match the clinical presentation of agammaglobulinemia with cerebellar involvement (though cerebellar atrophy is atypical for XLA, it's more consistent than ATM given absent B cells).", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-009", "question": "A 55-year-old man with alcoholic cirrhosis presents with hepatic encephalopathy refractory to lactulose and rifaximin. He has recurrent episodes requiring hospitalization every 2-3 weeks. Transjugular intrahepatic portosystemic shunt (TIPS) is not an option due to severe pulmonary hypertension. Which of the following interventions has the strongest evidence for reducing recurrent hepatic encephalopathy in this patient?", "options": ["Daily polyethylene glycol 3350 17 g", "Empirical vancomycin 125 mg four times daily", "Oral L-ornithine L-aspartate 6 g three times daily", "Sodium benzoate 5 g twice daily", "Branch-chain amino acid supplementation three times daily"], "answer": "A", "answer_index": 0, "explanation": "Polyethylene glycol has been shown in randomized trials to be more effective than lactulose for acute hepatic encephalopathy and may reduce recurrence by more effectively clearing ammonia-producing bacteria from the gut. Vancomycin has similar efficacy to rifaximin but risk of resistance. L-ornithine L-aspartate has modest benefit as adjunct only. Sodium benzoate is second-line. Branch-chain amino acids improve nutrition but not specifically encephalopathy recurrence.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "```json\n{\n    \"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - a unique best answer exists but option A is not it. Key stem clues: refractory hepatic encephalopathy despite lactulose/rifaximin, recurrent hospitalizations every 2-3 weeks, TIPS contraindicated due to pulmonary hypertension. Main logical issue: The keyed answer (A) lacks strong evidence for reducing recurrent hepatic encephalopathy in this chronic refractory outpatient scenario. Polyethylene glycol has evidence for acute HE treatment but not specifically for reducing recurrence in refractory cases. Main medical accuracy issue: Option B (empirical vancomycin) has the strongest evidence base for reducing recurrent HE in patients failing standard therapy, supported by guidelines and trials showing efficacy similar to rifaximin. Minimal fix: Change key to B (empirical vancomycin) or modify stem to specify acute treatment rather than recurrence prevention.\",\n    \"medical_accuracy_score\": 3,\n    \"logical_validity\": false,\n    \"logical_false_reason\": \"K\"\n}\n```", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - a unique best answer exists but option A is not it. Key stem clues: refractory hepatic encephalopathy despite lactulose/rifaximin, recurrent hospitalizations every 2-3 weeks, TIPS contraindicated due to pulmonary hypertension. Main logical issue: The keyed answer (A) lacks strong evidence for reducing recurrent hepatic encephalopathy in this chronic refractory outpatient scenario. Polyethylene glycol has evidence for acute HE treatment but not specifically for reducing recurrence in refractory cases. Main medical accuracy issue: Option B (empirical vancomycin) has the strongest evidence base for reducing recurrent HE in patients failing standard therapy, supported by guidelines and trials showing efficacy similar to rifaximin. Minimal fix: Change key to B (empirical vancomycin) or modify stem to specify acute treatment rather than recurrence prevention.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-010", "question": "A 34-year-old woman with metastatic HER2-positive breast cancer on trastuzumab, pertuzumab, and docetaxel presents with acute decompensated heart failure. Echocardiography shows global hypokinesis with LVEF 20%, markedly reduced from baseline 55%. Which of the following biomarkers would be most specific for differentiating trastuzumab-induced cardiomyopathy from anthracycline-like toxicity?", "options": ["Elevated serum troponin I with normal NT-proBNP", "Markedly elevated NT-proBNP with normal troponin", "Elevated soluble ST2 with normal galectin-3", "Increased urinary 8-hydroxy-2'-deoxyguanosine", "Elevated growth differentiation factor-15 (GDF-15)"], "answer": "A", "answer_index": 0, "explanation": "Trastuzumab-induced cardiotoxicity typically presents with elevated troponin (indicating myocyte injury) but relatively preserved NT-proBNP (less volume overload/stretch), reflecting its mechanism of reversible HER2 receptor blockade without direct cellular damage. Anthracycline toxicity shows both elevated troponin and markedly elevated NT-proBNP due to irreversible cellular damage. ST2 and galectin-3 are fibrosis markers not specific to this distinction. 8-OHdG is oxidative stress marker. GDF-15 is elevated in various cardiac conditions.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "```json\n{\n    \"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - a unique best answer exists but the provided key (A) is not it. Key stem clues: Acute decompensated heart failure in a patient on trastuzumab with global hypokinesis and severe LVEF drop. The question asks for the most specific biomarker to differentiate trastuzumab-induced cardiomyopathy from anthracycline-like toxicity. Main logical issue: The keyed answer (A) contradicts established knowledge - both trastuzumab and anthracycline cardiotoxicity typically show elevated troponin, and NT-proBNP is commonly elevated in heart failure regardless of etiology. Main medical accuracy issue: The rationale's claim that trastuzumab cardiotoxicity shows 'relatively preserved NT-proBNP' is incorrect in acute decompensated heart failure. Minimal fix: Change key to E (GDF-15), which has emerging evidence for differentiating cardiotoxicity types, and adjust rationale to reflect that NT-proBNP would be elevated in decompensated heart failure regardless of cause.\",\n    \"medical_accuracy_score\": 2,\n    \"logical_validity\": false,\n    \"logical_false_reason\": \"K\"\n}\n```", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - a unique best answer exists but the provided key (A) is not it. Key stem clues: Acute decompensated heart failure in a patient on trastuzumab with global hypokinesis and severe LVEF drop. The question asks for the most specific biomarker to differentiate trastuzumab-induced cardiomyopathy from anthracycline-like toxicity. Main logical issue: The keyed answer (A) contradicts established knowledge - both trastuzumab and anthracycline cardiotoxicity typically show elevated troponin, and NT-proBNP is commonly elevated in heart failure regardless of etiology. Main medical accuracy issue: The rationale's claim that trastuzumab cardiotoxicity shows 'relatively preserved NT-proBNP' is incorrect in acute decompensated heart failure. Minimal fix: Change key to E (GDF-15), which has emerging evidence for differentiating cardiotoxicity types, and adjust rationale to reflect that NT-proBNP would be elevated in decompensated heart failure regardless of cause.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}]